ANI PHARMACEUTICALS, INC. (NASDAQ:ANIP) Files An 8-K Regulation FD Disclosure

23

ANI PHARMACEUTICALS, INC. (NASDAQ:ANIP) Files An 8-K Regulation FD Disclosure

Item 7.01

Regulation FD Disclosure.

On June 19, 2017, ANI Pharmaceuticals, Inc. (the Company, we or
us) posted to its website its June 2017 Investor Presentation. We
may use this presentation in our communications or at
conferences. The presentation is available on our website,
www.anipharmaceuticals.com, and is attached to this Current
Report on Form 8-K as Exhibit 99.1 and incorporated into this
Item 7.01 by reference.

In accordance with General Instruction B.2 of Form 8-K, the
information in this Current Report on Form 8-K, including Exhibit
99.1, shall not be deemed to be filed for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the Exchange
Act), or otherwise subject to the liabilities of that section,
and shall not be incorporated by reference into any registration
statement or other document filed under the Securities Act of
1933, as amended, or the Exchange Act, except as shall be
expressly set forth by specific reference in such filing.

Forward-Looking Statements

Certain statements contained in the presentation slides furnished
with this report contain forward-looking statements within the
meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Such statements include, but are
not limited to, statements about future operations, products,
financial position, operating results, prospects, pipeline or
potential markets therefor, and other statements that are not
historical in nature, particularly those that utilize terminology
such as anticipates, will, expects, plans, potential, future,
believes, intends, continue, other words of similar meaning,
derivations of such words, and the use of future dates.

Uncertainties and risks may cause our actual results to be
materially different than those expressed in or implied by such
forward-looking statements. Uncertainties and risks include, but
are not limited to, the risk that we may face with respect to
importing raw materials, increased competition, acquisitions,
contract manufacturing arrangements, delays or failure in
obtaining product approval from the U.S. Food and Drug
Administration (FDA), general business and economic conditions,
market trends, product development, regulatory and other
approvals and marketing.

More detailed information on these and additional factors that
could affect our actual results are described in our filings with
the Securities and Exchange Commission, including our most recent
annual report on Form 10-K and quarterly reports on Form 10-Q, as
well as our proxy statement/prospectus, filed with the Securities
and Exchange Commission on April 14, 2016. The forward-looking
statements contained in this document are made only as of the
date of this document. We undertake no obligation to update or
revise any forward-looking statement, whether as a result of new
information, future events or otherwise.

Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Exhibit
99.1 ANI Pharmaceuticals, Inc. Investor Presentation, June 2017



ANI PHARMACEUTICALS INC Exhibit
EX-99.1 2 v469176_ex99-1.htm EXHIBIT 99.1   Exhibit 99.1   A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Investor Presentation June 20,…
To view the full exhibit click here
About ANI PHARMACEUTICALS, INC. (NASDAQ:ANIP)

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations. Its generic products include Esterified Estrogen with Methyltestosterone, Etodolac, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup, Nimodipine, Opium Tincture, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Lithobid, Reglan and Vancocin. It has over two pharmaceutical manufacturing facilities located in Baudette, Minnesota that are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products. Its two facilities have a combined manufacturing, packaging and laboratory capacity totaling approximately 173,000 square feet.

An ad to help with our costs